Information:
Fel:
ID
32714
Beskrivning
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis
Nyckelord
Versioner (1)
- 2018-11-13 2018-11-13 -
Rättsinnehavare
GSK group of companies
Uppladdad den
13 november 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Estimation of Dose Proportionality of Darapladib - 107038
PGx-Pharmacogenetic Research Withdrawal of Consent
- StudyEvent: ODM
Similar models
PGx-Pharmacogenetic Research Withdrawal of Consent
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
PGx-Pharmacogenetic Research Withdrawal of Consent
Has subject withdrawn consent for PGx-Pharmacogenetic research?
Item
Has subject withdrawn consent for PGx-Pharmacogenetic research?
boolean
Has a request been made for sample destruction?
Item
Has a request been made for sample destruction?
boolean
CL Item
Subject requested (1)
CL Item
Screen failure (2)
CL Item
Other (3)
If OTHER, specify
Item
If OTHER, specify
text